The Altura Abdominal Aortic Aneurysm (AAA) Endograft Safety and Feasibility Study

Inclusion Criteria: * 18 years or older. * Subject or subject's legal representative understands and has signed an informed consent. * Infrarenal aneurysmal neck diameter between 18 and 28mm, inclusive. * Abdominal aneurysm neck angulation \< 45 degrees. * Infrarenal non-aneurysmal neck \>/= 15mm in length. * Abdominal aneurysm \>4.5cm and growth \>1.0 cm/yr. * Limited iliac artery tortuosity. * Iliac artery fixation length of \>/= 15mm. * Iliac artery diameter between 8 and 19 mm, inclusive. * Iliac artery diameter accessible by a 14 Fr introducer. * Subject is a candidate for open surgical repair of abdominal aortic aneurysm. * Patent iliac or femoral arteries access vessels, size and morphology to allow endovascular access of 14 Fr introducer sheaths and catheters. * Subject has \> one year life expectancy. * Subject is not placed at additional risk while waiting for additional imaging necessary for vascular treatment. * Subject is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive. * Subject is able and willing to comply with 30 day, six (6) month, one (1) year and 2 (two) year follow-up. Exclusion Criteria: * Subject has an acutely ruptured or leaking or emergent aneurysm. * Subject has a dissecting aneurysm. * Subject has a mycotic or infected aneurysm. * Subject has current vascular injury due to trauma. * Subject's aneurysm is thoracic or suprarenal. * Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm. * Subject has thrombus, calcification and/or plaque that may compromise sealing * Subject has had a myocardial infarction within six (6) months prior to enrollment. * Subject has current angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia, or valvular disease. * Subject has undergone other major surgery within the 30 days prior to enrollment. * Subject is pregnant or nursing. * Known allergy to nitinol or polyester or contrast material that cannot be pretreated. * Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta. * Subject has connective tissue disease (e.g., Marfan's syndrome). * Subject has a bleeding disorder or anemia defined as hemoglobin \< 9.0 mg/dL. * Subject is hypercoagulable. * Subject is on dialysis or has compromised renal function as reflected by a serum creatinine \>2.2 mg/dL. * Subject has compromised hepatic function as measured by SGPT (ALT) \> three (3) times the upper limit of normal. * Subject has active systemic infection. * Subject is participating in another research study involving an investigational agent for the treatment of AAA. * Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.